CAM
IONS icon

Congress Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Congress Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,946
Closed -$296K – 403
2026
Q1 		$296K Buy
+3,946
New +$311K ﹤0.01% 404

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Congress Asset Management's IONS Position: Q2 2026 in Review

Congress Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 3,946 shares — an estimated $296K sold.

Congress Asset Management first reported a position in IONS in Q1 2026 and held it in 1 quarter. The position peaked at $296K in Q1 2026. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Congress Asset Management reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Congress Asset Management sold 3,946 Ionis Pharmaceuticals shares in Q2 2026, an estimated $296K.
  • Congress Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Congress Asset Management's Ionis Pharmaceuticals position peaked at $296K in Q1 2026.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.